{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:53:31Z","timestamp":1786488811324,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106775","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:11:57Z","timestamp":1758604317000},"page":"106775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Progression independent of relapse activity (PIRA) in the Era of high-efficacy treatments"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-8343","authenticated-orcid":false,"given":"Ricardo","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Barbara","family":"Eizaguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Pita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mainella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felisa","family":"Leguizamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena Mariela","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Tizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora Fernandez","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Piedrabuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Liwacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Miguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106775_bib0001","doi-asserted-by":"crossref","unstructured":"Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials. Sci. Rep. 2023 Sep 11;13(1):15003. doi: 10.1038\/s41598-023-40940-w.","DOI":"10.1038\/s41598-023-40940-w"},{"issue":"11","key":"10.1016\/j.msard.2025.106775_bib0002","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","year":"2023","journal-title":"JAMa Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106775_bib0003","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/acn3.52118","article-title":"A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis","volume":"11","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106775_bib0004","article-title":"Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies","volume":"9","author":"Alonso","year":"2023","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106775_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104935","article-title":"Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"79","author":"Alonso","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106775_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106775_bib0007","unstructured":"ClinicalTrials.gov (NCTNCT03375177)."},{"key":"10.1016\/j.msard.2025.106775_bib0008","series-title":"Guideline On Clinical Investigation of Medicinal Products For the Treatment of Multiple Sclerosis","year":"2015"},{"key":"10.1016\/j.msard.2025.106775_bib0009","doi-asserted-by":"crossref","unstructured":"Smouldering multiple sclerosis: the 'real MS' Gavin Giovannoni doi: 10.1177\/17562864211066751.","DOI":"10.1177\/17562864211066751"},{"key":"10.1016\/j.msard.2025.106775_bib0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomised clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMa Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106775_bib0011","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106775_bib0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106775_bib0013","doi-asserted-by":"crossref","unstructured":"Relapse-associated and relapse-independent contribution to overall expanded disability status scale progression in multiple sclerosis patients diagnosed in different eras Noemi Montobbio doi: 10.1002\/ana.27093.","DOI":"10.1002\/ana.27093"},{"issue":"8","key":"10.1016\/j.msard.2025.106775_bib0014","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1093\/brain\/awac111","article-title":"Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study","volume":"145","author":"Portaccio Bellinvia","year":"2022","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2025.106775_bib0015","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1212\/NXI.0000000000001059","article-title":"Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis","volume":"8","author":"Prosperini","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106775_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/jpm12010006","article-title":"Recommendations for the diagnosis and treatment of multiple sclerosis relapses","volume":"12","author":"Ramo-Tello","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.msard.2025.106775_bib0017","series-title":"R: A language and Environment For Statistical Computing","author":"Team","year":"2013"},{"issue":"2","key":"10.1016\/j.msard.2025.106775_bib0018","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.msard.2025.106775_bib0019","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458519877810","article-title":"The long-term outcomes of CIS patients in the Barcelona inception cohort: looking back to recognise aggressive MS","volume":"26","author":"Tintor\u00e9","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106775_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMa Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:37:40Z","timestamp":1784345860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"alternative-id":["S2211034825005176"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106775","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression independent of relapse activity (PIRA) in the Era of high-efficacy treatments","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106775"}}